

# Causal Mediation Analysis for Stochastic Interventions Nima S. Hejazi and Iván Díaz

Graduate Group in Biostatistics, UC Berkeley Division of Biostatistics, Weill Cornell Medicine

## OVERVIEW & MOTIVATIONS

- We consider the problem of efficiently estimating the effect of a stochastic shift interventions in studies with two-phase sampling of the treatment.
- We present an estimator of the average counterfactual outcome under a stochastic shift intervention with
  - consistency and efficiency guarantees,
  - a multiple double robustness property.
- The proposed estimator is asymptotically normal with estimable variance, thereby allowing for the construction of confidence intervals and hypothesis tests.
- The *txshift* R package [2] implements these estimators and leverages state-of-the-art machine learning in the procedure.

#### DATA: HIV VACCINE TRIALS

- Our approach is motivated by application to investigations of the effects of immune responses on HIV vaccine efficacy.
- Question: How does risk of HIV infection differ under shifts of an immune response in the vaccine arm of an efficacy trial?
- We simulate a data structure based on the HVTN 505 HIV-1 efficacy trial, as in [3]:
  - 2504 participants, with all observed cases matched to controls.
  - Background (W): sex, age, BMI, etc.
  - Intervention (*A*): immunobiomarkers (i.e., T-Cell profiles from ICS assays on preserved HIV-1-stimulated PBMCs).
  - Outcome (Y): HIV-1 infection status.
- Takeaway: Variable importance measure for ranking immune responses by utility as immunogenicity study endpoints in all future HIV-1 vaccine efficacy trials.

# METHODOLOGY I: THE EFFECT OF A STOCHASTIC INTERVENTION

- Consider  $X = (W, A, Y) \sim P_0^X \in \mathcal{M}$ , where W is a set of baseline covariates, A a treatment, and Y an outcome of interest, with no assumptions placed on the statistical model  $\mathcal{M}$ .
- Consider a shift of the treatment (i.e., d(A, W)) so that  $A = A + \delta$  for a user-specified shift  $\delta$ .
- To protect against violations of the assumption of positivity, the shifting mechanism may be made a function of the observed data, where u(w) is the maximum shift with support in the data:

$$d(a, w) = \begin{cases} a + \delta, & a + \delta < u(w) \\ a, & \text{otherwise} \end{cases}$$

• The causal parameter is identified by the observed data parameter [4]:

$$\Psi(P_0^X) = \mathbb{E}_{P_0} \overline{Q}(d(A, W), W), \tag{1}$$

where  $\overline{Q}(d(A, W), W)$  is the conditional mean of the outcome given A = d(A, W) and W.

• The efficient influence function (EIF) of  $\Psi$  relative to a nonparametric model is

$$D^{F}(P_{0}^{X})(x) = H(a, w)(y - \overline{Q}(a, w)) + \overline{Q}(d(a, w), w) - \Psi(P_{0}^{X})(x), \tag{2}$$

where the auxiliary term, H(a, w), may be expressed as

$$H(a, w) = \mathbb{I}(a < u(w)) \frac{g(a - \delta \mid w)}{g(a \mid w)} + \mathbb{I}(a \ge u(w) - \delta).$$
(3)

#### METHODOLOGY II: CORRECTIONS FOR TWO-PHASE SAMPLING

- In the HVTN 505 HIV-1 trial, all infected participants and the matched subset of controls have A (immunobiomarkers) measured, thus making the observed data structure  $O = (W, \Delta A, Y) \sim P_0$ .
  - $\Delta \in \{0,1\}$  is the missingness mechanism introduced by sampling, under which the observed immune response ( $\Delta A$ ) is arbitrarily set to 0 when unobserved.
  - We assume that, given V := (W, Y),  $\Delta$  is Bernoulli distributed with probability  $\Pi_0(V)$ .
- The IPCW-TMLE [5] estimates the target parameter by adding *inverse weights* to the loss function.
- Improvements in the efficiency are attainable using a TMLE based on the EIF:

$$D(P_0)(o) = \frac{\Delta}{\Pi(v)} D^F(P_0^X)(x) - \left(1 - \frac{\Delta}{\Pi(v)}\right) \mathbb{E}(D^F(P_0^X)(x) \mid \Delta = 1, V = v)$$

- This augmented estimator exhibits several desirable properties
  - efficiency, achieving the CR bound for the class of regular asymptotically linear estimators;
  - multiple robustness, consistency of the parameter estimate when one of (g,Q) and one of  $(\Pi, \mathbb{E}_0(D^F(P_0^X)(X) \mid \Delta = 1, V))$  is consistently estimated;
  - valid statistical inference even when  $\Pi$  is estimated nonparametrically.

### RESULTS & DISCUSSION

- All estimators approx. unbiased in large samples; however, inefficient TMLE with HAL has bias not converging at  $n^{-\frac{1}{2}}$ .
- Fitting II with HAL or GLM, efficient TMLE has lower variance than the inefficient.

#### REFERENCES

- [1] I. Díaz and M. J. van der Laan, "Stochastic treatment regimes," in *Targeted Learning in Data Science: Causal Inference for Complex Longitudinal Studies*. Springer Science & Business Media, 2018, pp. 167–180.
- [2] N. S. Hejazi, M. J. van der Laan, and D. C. Benkeser, *txshift: Targeted Learning of Causal Effects under Stochastic Treatment Regimes in R*, 2018, r package version 0.2.0. [Online]. Available: https://github.com/nhejazi/txshift
- [3] H. E. Janes, K. W. Cohen, N. Frahm, S. C. De Rosa, B. Sanchez, J. Hural, C. A. Magaret, S. Karuna, C. Bentley, R. Gottardo *et al.*, "Higher t-cell responses induced by dna/rad5 hiv-1 preventive vaccine are associated with lower hiv-1 infection risk in an efficacy trial," *The*
- Journal of infectious diseases, vol. 215, no. 9, pp. 1376–1385, 2017.

  [4] I. D. Muñoz and M. J. van der Laan, "Population intervention causal effects based on stochastic interventions," *Biometrics*, vol. 68, no. 2, pp. 541–549, 2012.
- [5] S. Rose and M. J. van der Laan, "A targeted maximum likelihood estimator for two-stage designs," *The International Journal of Biostatistics*, vol. 7, no. 1, pp. 1–21, 2011.

#### CONTACT INFORMATION

- N.S. Hejazi, Ph.D. student, Graduate Group in Biostatistics, NHE-JAZI@BERKELEY.EDU
- I. Diaz: Assistant Professor of Biostatistics,